ClinicalTrials.gg
CompletedNCT05815498NextCOVEUpdated May 1, 2026Results posted

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

A Phase 3 interventional study of mRNA-1283.222 and mRNA-1273.222 in COVID-19, sponsored by ModernaTX, Inc.. Completed at 230 sites in 4 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13,553
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..

Enrollment
3rd of 22
13,553 · median 988
Started
2023
with 4 others
Phase 3
6 of 34
none open now
Registered
18th of 34
by date

Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 3rd largest by enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2023, is one of 6 in phase 3, and was the 18th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in COVID-19 by Moderna, Inc., or all of them as a file.
02

Study summary

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).

03

Conditions studied

  • COVID-19

Keywords

  • mRNA-1283.222
  • mRNA-1273.222
  • mRNA-1283.815
  • mRNA-1273.815
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Investigator's assessment that the participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures.
  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, and agreement to continue adequate contraception or abstinence through 90 days following the vaccine administration.
  • Part 1: Has previously received a primary series of an authorized/approved COVID-19 vaccine. For participants ≥18 years of age, at least 1 booster dose must have also been received. Proof of prior vaccination is required. A heterologous vaccine regimen is acceptable.

Part 2: No prior vaccination is required. For participants who have been previously vaccinated, proof of vaccination is required.

Key Exclusion Criteria:

  • Has had close contact, as defined by the Centers for Disease Control and Prevention (CDC), with someone who had a SARS-CoV-2 infection in the past 14 days, or COVID-19 in the past 10 days.
  • Participant is acutely ill or febrile (temperature ≥38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
  • Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
  • Has received systemic or immune-modifying drugs for >14 days in total within 181 days prior to Screening (for ≥10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Has received or plans to receive any licensed vaccine ≤60 days prior to the study injection (Day 1) or plans to receive a licensed vaccine within 60 days after the study injection.
  • Has received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive during the study.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
  • Has participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13,553 participants (actual)

Study arms

  • Experimental
    Part 1: mRNA-1283.222

    Participants will receive single intramuscular (IM) injection of mRNA-1283.222 on Day 1.

    Biological: mRNA-1283.222

  • Experimental
    Part 1: mRNA-1273.222

    Participants will receive single IM injection of mRNA-1273.222 on Day 1.

    Biological: mRNA-1273.222

  • Experimental
    Part 2: mRNA-1283.815

    Participants will receive single IM injection of mRNA-1283.815 on Day 1.

    Biological: mRNA-1283.815

  • Experimental
    Part 2: mRNA-1273.815

    Participants will receive single IM injection of mRNA-1273.815 on Day 1.

    Biological: mRNA-1273.815

Interventions

  • BiologicalmRNA-1283.222

    Sterile liquid for injection

  • BiologicalmRNA-1273.222

    Sterile liquid for injection

  • BiologicalmRNA-1283.815

    Sterile liquid for injection

  • BiologicalmRNA-1273.815

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29

    Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 103 arbitrary units (AU)/milliliter (mL) and ULOQ was 28571 AU/mL.

    Time frame: Day 29

  2. Part 1: Seroresponse Rate (SRR) Omicron BA.4/5 at Day 29

    Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL.

    Time frame: Day 29

  3. Part 1: GM of the Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) D614G at Day 29

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL.

    Time frame: Day 29

  4. Part 1: SRR of Ancestral SARS-CoV-2 D641G at Day 29

    Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 10 AU/mL and ULOQ was 111433AU/mL.

    Time frame: Day 29

  5. Part 1: Number of Participants With First Event of Centers for Disease Control and Prevention (CDC)-Defined COVID-19

    CDC COVID-19 definition: the presence of at least 1 CDC listed symptom and positive reverse transcriptase polymerase chain reaction (RT-PCR) test on a respiratory sample.

    Time frame: From 14 days after injection up to Day 365

  6. Part 1: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to Day 7 (7-day follow-up after vaccination)

  7. Part 3: Number of Participants With Solicited Local and Systemic ARs

    Solicited ARs were recorded daily using eDiaries. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to Day 7 (7-day follow-up after vaccination)

  8. Part 1: Number of Participants With Unsolicited Adverse Events (AEs)

    An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Day 28 (28-day follow-up after vaccination)

  9. Part 3: Number of Participants With Unsolicited AEs

    An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Day 28 (28-day follow-up after vaccination)

  10. Part 1: Number of Participants With Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs)

    SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 365

  11. Part 3: Number of Participants With Any SAEs, MAAEs, AEs Leading to Withdrawal From Study, and AESIs

    SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 up to Day 181

Secondary outcomes

  1. Part 1: GMs of Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.

    Time frame: Days 91, 181, and 365

  2. Part 1: SRR Against Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G at Days 91, 181, and 365

    Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.

    Time frame: Days 91, 181, and 365

  3. Part 1: Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)

    SARS-CoV-2 infection (symptomatic or asymptomatic) was defined as (1) negative binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein and negative RT-PCR at baseline that became positive bAb level against SARS-CoV-2 nucleocapsid protein post-baseline, or (2) positive RT-PCR post-baseline. Asymptomatic SARS-CoV-2 infection was characterized by the absence of COVID-19 symptoms.

    Time frame: From 14 days after injection up to Day 365

  4. Part 3: GM of Omicron XBB.1.5 in Unvaccinated Participants

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

    Time frame: Day 29

  5. Part 3: GM of Omicron XBB.1.5 in All Study Participants

    Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

    Time frame: Day 29

  6. Part 3: SRR Against Omicron XBB.1.5 in Unvaccinated Participants

    Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

    Time frame: Day 29

  7. Part 3: SRR Against Omicron XBB.1.5 in All Study Participants

    Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

    Time frame: Day 29

07

Results

Posted May 1, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815
Started5728572510561044
Received at least 1 dose of study drug5706571010521039
Per-protocol immunogenicity subset (ppis)623568994967
Solicited safety set5702570510521039
Completed53125373991967
Not completed4163526577
Withdrew: Adverse event4210
Withdrew: Death71101
Withdrew: Lost to follow-up1801523954
Withdrew: Physician decision141021
Withdrew: Pregnancy2000
Withdrew: Protocol violation2100
Withdrew: Withdrawal by subject1811571715
Withdrew: Other than specified4421
Withdrew: Randomized but not treated221545

Outcome measures

PrimaryPart 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29

Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 103 arbitrary units (AU)/milliliter (mL) and ULOQ was 28571 AU/mL.

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29
AU/mLPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 292340.9 ± 2167.01753.8 ± 1618.2
Statistical analysis
  • Part 1: mRNA-1283.222 vs Part 1: mRNA-1273.222 · Gmr: 1.335 · 95% CI 1.194 to 1.492
PrimaryPart 1: Seroresponse Rate (SRR) Omicron BA.4/5 at Day 29

Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Part 1: Seroresponse Rate (SRR) Omicron BA.4/5 at Day 29
percentage of participantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: Seroresponse Rate (SRR) Omicron BA.4/5 at Day 2979.9 ± 76.565.5 ± 61.4
Statistical analysis
  • Part 1: mRNA-1283.222 vs Part 1: mRNA-1273.222 · Srr difference: 14.4 · 95% CI 9.3 to 19.4
PrimaryPart 1: GM of the Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) D614G at Day 29

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL.

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part 1: GM of the Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) D614G at Day 29
AU/mLPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: GM of the Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) D614G at Day 2910631.9 ± 9960.28576.5 ± 8012.5
Statistical analysis
  • Part 1: mRNA-1283.222 vs Part 1: mRNA-1273.222 · Gmr: 1.240 · 95% CI 1.128 to 1.362
PrimaryPart 1: SRR of Ancestral SARS-CoV-2 D641G at Day 29

Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 10 AU/mL and ULOQ was 111433AU/mL.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Part 1: SRR of Ancestral SARS-CoV-2 D641G at Day 29
percentage of participantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: SRR of Ancestral SARS-CoV-2 D641G at Day 2983.6 ± 80.472.9 ± 69.0
Statistical analysis
  • Part 1: mRNA-1283.222 vs Part 1: mRNA-1273.222 · Srr difference: 10.7 · 95% CI 6.0 to 15.4
PrimaryPart 1: Number of Participants With First Event of Centers for Disease Control and Prevention (CDC)-Defined COVID-19

CDC COVID-19 definition: the presence of at least 1 CDC listed symptom and positive reverse transcriptase polymerase chain reaction (RT-PCR) test on a respiratory sample.

Time frame:
From 14 days after injection up to Day 365
Reported as:
Count of participants · Participants
Part 1: Number of Participants With First Event of Centers for Disease Control and Prevention (CDC)-Defined COVID-19
ParticipantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: Number of Participants With First Event of Centers for Disease Control and Prevention (CDC)-Defined COVID-19560617
Statistical analysis
  • Part 1: mRNA-1283.222 vs Part 1: mRNA-1273.222 · Cox proportional hazard model · p = = 0.0005 · Rve: 9.31 · 99.4% CI -6.58 to 22.83
PrimaryPart 1: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to Day 7 (7-day follow-up after vaccination)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)45714781
PrimaryPart 3: Number of Participants With Solicited Local and Systemic ARs

Solicited ARs were recorded daily using eDiaries. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to Day 7 (7-day follow-up after vaccination)
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Solicited Local and Systemic ARs
ParticipantsPart 3: mRNA-1283.815Part 3: mRNA-1273.815
Part 3: Number of Participants With Solicited Local and Systemic ARs767799
PrimaryPart 1: Number of Participants With Unsolicited Adverse Events (AEs)

An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Day 28 (28-day follow-up after vaccination)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: Number of Participants With Unsolicited Adverse Events (AEs)706683
PrimaryPart 3: Number of Participants With Unsolicited AEs

An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Day 28 (28-day follow-up after vaccination)
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Unsolicited AEs
ParticipantsPart 3: mRNA-1283.815Part 3: mRNA-1273.815
Part 3: Number of Participants With Unsolicited AEs7376
PrimaryPart 1: Number of Participants With Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs)

SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 365
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Any Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study, and AEs of Special Interest (AESIs)
ParticipantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
SAEs203197
MAAEs21652120
AEs Leading to Withdrawal From Study1113
AESIs7975
SecondaryPart 1: GMs of Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.

Time frame:
Days 91, 181, and 365
Reported as:
Geometric mean · AU/mL
Part 1: GMs of Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G
AU/mLPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Omicron BA.4/5: Day 911513.2 (1400.9 to 1634.5)1137.8 (1049.8 to 1233.3)
Omicron BA.4/5: Day 1811113.3 (1022.4 to 1212.3)863.7 (792.1 to 941.9)
Omicron BA.4/5: Day 365753.3 (690.2 to 822.2)625.9 (572.8 to 684.0)
SARS-CoV-2 D614G: Day 916537.7 (6086.0 to 7023.0)5414.0 (5023.9 to 5834.3)
SARS-CoV-2 D614G: Day 1814753.2 (4381.5 to 5156.5)3861.8 (3555.3 to 4194.6)
SARS-CoV-2 D614G: Day 3652878.9 (2645.2 to 3133.3)2545.0 (2335.6 to 2773.2)
SecondaryPart 1: SRR Against Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G at Days 91, 181, and 365

Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to pre-booster. LLOQ was 103 AU/mL and ULOQ was 28571 AU/mL for Omicron BA.4/5. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for ancestral SARS-CoV-2 D614G.

Time frame:
Days 91, 181, and 365
Reported as:
Number · percentage of participants
Part 1: SRR Against Omicron BA.4/5 and Ancestral SARS-CoV-2 D614G at Days 91, 181, and 365
percentage of participantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Omicron BA.4/5: Day 9159.5 (55.5 to 63.4)45.8 (41.6 to 50.1)
Omicron BA.4/5: Day 18145.7 (41.4 to 50.0)37.1 (33.0 to 41.4)
Omicron BA.4/5: Day 36530.0 (26.1 to 34.2)26.4 (22.6 to 30.6)
SARS-CoV-2 D614G Day 9164.8 (60.8 to 68.6)52.9 (48.6 to 57.1)
SARS-CoV-2 D614G Day 18145.6 (41.3 to 49.9)39.0 (34.8 to 43.4)
SARS-CoV-2 D614G Day 36526.3 (22.5 to 30.4)25.4 (21.6 to 29.5)
SecondaryPart 1: Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)

SARS-CoV-2 infection (symptomatic or asymptomatic) was defined as (1) negative binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein and negative RT-PCR at baseline that became positive bAb level against SARS-CoV-2 nucleocapsid protein post-baseline, or (2) positive RT-PCR post-baseline. Asymptomatic SARS-CoV-2 infection was characterized by the absence of COVID-19 symptoms.

Time frame:
From 14 days after injection up to Day 365
Reported as:
Count of participants · Participants
Part 1: Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)
ParticipantsPart 1: mRNA-1283.222Part 1: mRNA-1273.222
Part 1: Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)12491290
PrimaryPart 3: Number of Participants With Any SAEs, MAAEs, AEs Leading to Withdrawal From Study, and AESIs

SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AEs leading to the withdrawal from study reported for this endpoint also include the AEs that led to death. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 up to Day 181
Reported as:
Count of participants · Participants
Part 3: Number of Participants With Any SAEs, MAAEs, AEs Leading to Withdrawal From Study, and AESIs
ParticipantsPart 3: mRNA-1283.815Part 3: mRNA-1273.815
SAEs1520
MAAEs140126
AEs Leading to Withdrawal From Study11
AESIs25
SecondaryPart 3: GM of Omicron XBB.1.5 in Unvaccinated Participants

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part 3: GM of Omicron XBB.1.5 in Unvaccinated Participants
AU/mLPart 3: mRNA-1283.815Part 3: mRNA-1273.815
Part 3: GM of Omicron XBB.1.5 in Unvaccinated Participants2571.1 (2247.1 to 2941.7)1896.8 (1647.4 to 2183.9)
SecondaryPart 3: GM of Omicron XBB.1.5 in All Study Participants

Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part 3: GM of Omicron XBB.1.5 in All Study Participants
AU/mLPart 3: mRNA-1283.815Part 3: mRNA-1273.815
Part 3: GM of Omicron XBB.1.5 in All Study Participants2747.3 (2552.4 to 2957.1)2027.0 (1881.6 to 2183.7)
SecondaryPart 3: SRR Against Omicron XBB.1.5 in Unvaccinated Participants

Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Part 3: SRR Against Omicron XBB.1.5 in Unvaccinated Participants
percentage of participantsPart 3: mRNA-1283.815Part 3: mRNA-1273.815
Part 3: SRR Against Omicron XBB.1.5 in Unvaccinated Participants91.1 (87.7 to 93.8)87.0 (83.0 to 90.4)
SecondaryPart 3: SRR Against Omicron XBB.1.5 in All Study Participants

Seroresponse was defined as an antibody value change from baseline below the LLOQ to ≥4\*LLOQ, or at least a 4-fold rise if baseline was ≥LLOQ and \<4\*LLOQ, or at least a 2-fold rise if baseline was ≥4\*LLOQ, where baseline referred to last non-missing measurement on or before study vaccination day. LLOQ was 38 AU/mL and ULOQ was 6960 AU/mL.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Part 3: SRR Against Omicron XBB.1.5 in All Study Participants
percentage of participantsPart 3: mRNA-1283.815Part 3: mRNA-1273.815
Part 3: SRR Against Omicron XBB.1.5 in All Study Participants88.3 (86.1 to 90.2)81.2 (78.6 to 83.6)

Adverse events

Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation: Day 1 up to Day 365. Other (non-serious) AEs: up to 28 days after study injection, unless they met criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: mRNA-1283.2229/5,728 (0.2%)203/5,706 (3.6%)607/5,706 (10.6%)
Part 1: mRNA-1273.22211/5,725 (0.2%)197/5,710 (3.5%)636/5,710 (11.1%)
Part 3: mRNA-1283.8150/1,056 (0%)15/1,052 (1.4%)21/1,052 (2%)
Part 3: mRNA-1273.8151/1,044 (0.1%)20/1,039 (1.9%)16/1,039 (1.5%)
Most frequent serious events
Showing 10 of 299
Most frequent serious events
EventPart 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815
PneumoniaInfections and infestations6/570611/57101/10523/1039
Cardiac arrestCardiac disorders2/57061/57100/10522/1039
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/57061/57100/10522/1039
Suicidal ideationPsychiatric disorders3/57060/57102/10520/1039
Tibia fractureInjury, poisoning and procedural complications0/57061/57102/10521/1039
OsteoarthritisMusculoskeletal and connective tissue disorders10/57066/57100/10520/1039
Myocardial infarctionCardiac disorders7/57066/57100/10520/1039
Atrial fibrillationCardiac disorders4/57067/57100/10520/1039
Acute kidney injuryRenal and urinary disorders6/57062/57100/10520/1039
AppendicitisInfections and infestations4/57060/57101/10521/1039
Most frequent other events
Most frequent other events
EventPart 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815
Upper respiratory tract infectionInfections and infestations607/5706636/571021/105216/1039

Baseline characteristics

The Safety Set included all randomized participants who received study drug.

Age, Categorical
Age, Categorical(Participants)Part 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815Total
<=18 years4974955024951989
Between 18 and 65 years357535754534558058
>=65 years1634164097893460
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815Total
Female312030795595377295
Male258626314935026212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815Total
Hispanic or Latino7697412302531993
Not Hispanic or Latino4860486381577711315
Unknown or Not Reported7710679199
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: mRNA-1283.222Part 1: mRNA-1273.222Part 3: mRNA-1283.815Part 3: mRNA-1273.815Total
Race — White4670471169070010771
Race — Black or African American6406342882601822
Race — Asian2251832118447
Race — American Indian or Alaska Native20265859
Race — Native Hawaiian or Other Pacific Islander961319
Race — Multiple81944043258
Race — Other20202244
Race — Not Reported36265370
Race — Unknown5100217
08

Study locations

230 sites
  • Optimal Research
    Huntsville, Alabama 35802, United States
  • Accel Research Sites- Achieve Clinical Research
    Vestavia Hills, Alabama 35216, United States
  • Chandler Clinical Trials
    Chandler, Arizona 85224, United States
  • Phoenix Clinical Research LLC
    Phoenix, Arizona 85014, United States
  • FRC - CCT Research
    Phoenix, Arizona 85244, United States
  • Headlands Research Sarasota
    Scottsdale, Arizona 85260, United States
  • Clinical Research Consortium
    Tempe, Arizona 85281, United States
  • Noble Clinical Research, LLC
    Tucson, Arizona 85704, United States
  • Del Sol research Management LLC.
    Tucson, Arizona 85715, United States
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Velocity Clinical Research, Banning
    Banning, California 92220, United States
  • Velocity Clinical Research- Chula Vista
    Chula Vista, California 91911, United States
  • Benchmark Research
    Colton, California 92324, United States
  • Marvel Clinical Research 002, LLC
    Huntington Beach, California 92647, United States
  • Velocity Clinical Research Huntington Park
    Huntington Park, California 90255, United States
  • Velocity Clinical Research
    La Mesa, California 91942, United States
  • Chemidox Clinical Trials
    Lancaster, California 93534, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Velocity Clinical Research- Westlake
    Los Angeles, California 90057, United States
  • Velocity Clinical Research-North Hollywood
    North Hollywood, California 90036, United States
  • Empire Clinical Research
    Pomona, California 91786, United States
  • CenExel - CITrials
    Riverside, California 82506, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Benchmark Research
    Sacramento, California 95864, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Lynn Institute of Denver
    Aurora, Colorado 80012, United States
  • Velocity Clinical Research Denver
    Denver, Colorado 80209, United States
  • Tekton Research - Fort Collins
    Fort Collins, Colorado 80525, United States
  • Tekton Research, Inc- Longmont Center
    Longmont, Colorado 80501, United States
  • Alliance for Multispeciality Research - Miami
    Coral Gables, Florida 33134, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Beautiful Minds Clinical Research Center
    Cutler Bay, Florida 33157, United States
  • Clinical Research Partners LLC
    DeLand, Florida 32720, United States
  • Hillcrest Medical Research, LLC
    DeLand, Florida 32720, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale, Florida 33009, United States
  • Sweet Hope Research Specialty, Inc.
    Hialeah, Florida 33016, United States
  • CenExel Research Centers of America
    Hollywood, Florida 33024, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Encore Research Group-Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc
    Jacksonville, Florida 32256, United States
  • Health Awareness INC
    Jupiter, Florida 33458, United States
  • Accel Clinical Research
    Lakeland, Florida 33803, United States
  • Accel Research Sites
    Largo, Florida 33709, United States
  • Acclaim Clinical Research
    Maitland, Florida 32751, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • Clinical Trials of Florida
    Miami, Florida 33186, United States
  • Suncoast Research Associates, LLC
    Miami, Florida 33713, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Global Health Research Center, Inc.
    Miami Lakes, Florida 33016, United States
  • Clinical Neuroscience Solutions (CNS Healthcare site)
    Orlando, Florida 32801, United States
  • Headlands Research Orlando
    Orlando, Florida 32819, United States
  • Innovation Medical Research Center
    Palmetto Bay, Florida 33157, United States
  • Pines Care Research Center, Inc.
    Pembroke Pines, Florida 33024, United States
  • Suncoast Research Associates, LLC
    Pembroke Pines, Florida 33324, United States
  • Synexus
    Pinellas Park, Florida 33781, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Global Health Research Center, Inc.
    Tampa, Florida 33615, United States
  • Santos Research Center CORP
    Tampa, Florida 33615, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Delricht Research
    Atlanta, Georgia 30329, United States
  • Atlanta Clinical Research Center
    Atlanta, Georgia 30342, United States
  • Baybol Research Institute
    Chamblee, Georgia 30341, United States
  • Centricity Research
    Columbus, Georgia 31904, United States
  • Elite Research Network
    Decatur, Georgia 30030, United States
  • Accel Research Sites Lake Oconee
    Eatonton, Georgia 31024, United States
  • Georgia Clinic, PC/CCT Research
    Norcross, Georgia 30092, United States
  • Clinical Research Atlanta/Headlands
    Stockbridge, Georgia 30281, United States
  • Velocity Clinical Research
    Meridian, Idaho 83642, United States
  • Chicago Clinical Research Institute
    Chicago, Illinois 60607, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Velocity Clinical Research Valparaiso
    Valparaiso, Indiana 46383, United States
  • Alliance for Multispecialty Research, LLC
    El Dorado, Kansas 67042, United States
  • Johnson County Clin-Trials, Inc (JCCT)
    Lenexa, Kansas 66219, United States
  • Alliance for Multispecialty Research, LLC- Wichita
    Wichita, Kansas 67207, United States
  • Tekton Research Inc
    Wichita, Kansas 67218, United States
  • Alliance for Multispecialty Research-Lexington
    Lexington, Kentucky 40509, United States
  • Versailles Family Medicine
    Versailles, Kentucky 40383, United States
  • Meridian Clinical Research
    Baton Rouge, Louisiana 70809, United States
  • Benchmark Research
    Covington, Louisiana 70006, United States
  • MedPharmics
    Covington, Louisiana 70433, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Delricht Research
    New Orleans, Louisiana 70115, United States
  • Delricht Clinical Research
    Prairieville, Louisiana 70769, United States
  • Centennial Medical Group
    Eldridge, Maryland 21075, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • DM Clinical Research
    Brookline, Massachusetts 02445, United States
  • Great Lakes Research Institute
    Southfield, Michigan 48075, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Delricht Research
    Gulfport, Mississippi 39503, United States
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Delricht Research
    Springfield, Missouri 65807, United States
  • Sundance Clinical Research, LLC
    St Louis, Missouri 63141, United States
  • Delricht Research
    Town and Country, Missouri 63017, United States
  • Montana Medical Research, Inc
    Missoula, Montana 59808, United States
  • CCT research/ Methodist Physicians Clinic- Prairie Fields
    Fremont, Nebraska 68025, United States
  • Velocity Clinical Research
    Grand Island, Nebraska 68803, United States
  • Meridian Clinical Research, LLC
    Lincoln, Nebraska 68510, United States

Showing the first 100 of 230 sites across 4 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chalkias S, Dennis P, Petersen D, Radhakrishnan K, Vaughan L, Handforth R, Rossi A, Wahid R, Edwards DK, Feng J, Deng W, Zhou H, De Windt E, Urdaneta V, Paila Y, Girard B, Faust SN, Walsh SR, Cosgrove CA, Miller J, Das R. Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial. Lancet Infect Dis. 2025 Nov;25(11):1230-1242. doi: 10.1016/S1473-3099(25)00236-1. Epub 2025 Jul 7. PubMed 40639387 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Apr 2025, 24 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 24 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
Apr 18, 2023
StartActual
Mar 28, 2023
Primary completionActual
Apr 12, 2025
CompletionActual
Apr 12, 2025
Results first posted
May 1, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05815498
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Mar 28, 2023
Primary completion
Apr 12, 2025
Completion
Apr 12, 2025
Results posted
May 1, 2026
Last update
May 1, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elasomeran/Davesomeran

Start the discussion